What is Plasys300® and what can it be used for?
Plasys300® is a proprietary combination, which is specifically designed to facilitate healthy ageing in men.
Plasys300® is derived from a trusted source of pine bark and rye pollen to ensure the high-quality and purity of the final extract. The final ingredient is manufactured at Pharmactive’s own facilities, which are GMP-certified with other quality and environmental management certifications.
Taking advantage of the synergic effect of different bio-actives, it offers triple benefits in a single solution:
- urinary symptom improvement
- prostate enlargement inhibition
- hormonal balance
Its low dose avoids the use of multiple ingredients in the same formula, favouring the use of low-size formats, therefore enabling easy swallowing.
Plasys300® is standardized to ≥50% phytosterols (as β–sitosterol) by GC and to ≥1% essential amino
acids by HPLC. β–sitosterol is a phytosterol that has clinical evidence as an inhibitor of testosterone production.1-3
Essential amino acids from rye pollen have a potent antioxidant effect and have been related to anti-inflammatory properties, as well as clinical evidence for palliating benign prostate hyperplasia
symptoms (such as nocturia, urine frequency, bladder emptying and hyperplasia).4-11
Main Mechanisms of Action
Plasys300® acts mainly at three levels in a synergic way:
- It inhibits one of the enzymes responsible for testosterone production (5-α-reductase), decreasing its concentration in the prostate and balancing cellular growth factors levels (such as SDGF and EDGF)2 typically altered in an enlarged prostate or BPH.
- It blocks the overstimulation of α-adrenergic receptors at the prostate, reducing the urinary tract vasoconstriction as well as the urinary discomfort symptoms.10,12
- It has an anti-proliferative effect at the prostatic cells that helps prevent prostate
(1) Bergers A., et al. British J. of Urology. 2000; 85, 842-846; (2) Berges R.R., et al. Lancet. 1995; 345, 1529-1532; (3) Madersbacher S., et al. EAUEBU. 2007; 5, 197-205; (4) Buck A.C., et al. British J. of Urology. 1990; 66, 398-404; (5) Feinblatt H.M. and Gant J.C., J.Maine Med. Assn. 1958; 9, 99- 101; (6) Elist J. Urology. 2006; 67, 60-63; (6) Kimura M., et al. Japan Pharmacol. Ther. 1998; 26, 1801-1806; (7) Talpur N., et al. Mol Cell Biochem. 2003; 250, 21-26; (8) Yasumoto R., et al. Clin Therapy. 1995; 17, 82-86; (9) Inarejos-García A.M., et al. Nutr. Clín. Diet. Hosp. 2017; 37(supl. 1): 45; (10) Caine M., et al. British Journal of Urology. 1976; 48, 255-263; (11) Damrau F., et al. J Am Geriartr Soc. 1962; 10, 426-430; (12) Bartsch G., et al. European Urology. 2000; 37, 367-380;